Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-Tumor Necrosis Factor Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled Trials

Jennifer L. Jones, Gilaad G. Kaplan, Laurent Peyrin-Biroulet, Leonard Baidoo, Shane Devlin, Gil Y. Melmed, Divine Tanyingoh, Laura E. H. Raffals, Peter Irving, Patricia Kozuch, Miles Sparrow, Fernando Velayos, Brian Bressler, Adam Cheifetz, Jean Frederic Colombel, Corey A. Siegel

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Background & Aims: There is debate over whether patients with Crohn's disease who start anti-tumor necrosis factor (TNF) therapy after failed immunomodulator therapy should continue to receive concomitant immunomodulators. We conducted a meta-analysis of subgroups from randomized controlled trials (RCTs) of anti-TNF agents to compare the efficacy and safety of concomitant immunomodulator therapy vs anti-TNF monotherapy. Methods: We performed a systematic review of literature published from 1980 through 2008 and identified 11 RCTs of anti-TNF agents in patients with luminal or fistulizing Crohn's disease. We excluded RCTs of patients who were naive to anti-TNF and immunomodulator therapy. The primary end points were clinical response at weeks 4-14 and 24-30 and remission at weeks 24-30. Secondary end points included infusion site or injection site reactions and selected adverse events. A priori subgroup analyses were performed to evaluate fistula closure and the efficacy and safety of combination therapy with different anti-TNF agents. Results: Overall, combination therapy was no more effective than monotherapy in inducing 6-month remission (odds ratio [OR], 1.02; 95% confidence interval [CI], 0.80-1.31), inducing a response (OR, 1.08; 95% CI, 0.79-1.48), maintaining a response (OR, 1.53; 95% CI, 0.67-3.49), or inducing partial (OR, 1.25; 95% CI, 0.84-1.88) or complete fistula closure (OR, 1.10; 95% CI, 0.68-1.78). In subgroup analyses of individual anti-TNF agents, combination therapy was not more effective than monotherapy in inducing 6-month remission in those treated with infliximab (OR, 1.73; 95% CI, 0.97-3.07), adalimumab (OR, 0.88; 95% CI, 0.58-1.35), or certolizumab (OR, 0.93; 95% CI, 0.65-1.34). Overall, combination therapy was not associated with an increase in adverse events, but inclusion of infliximab was associated with fewer injection site reactions (OR, 0.46; 95% CI, 0.26-0.79.). Conclusions: On the basis of a meta-analysis, continued use of immunomodulator therapy after starting anti-TNF therapy is no more effective than anti-TNF monotherapy in inducing or maintaining response or remission. RCTs are needed to adequately assess the efficacy of continued immunomodulator therapy after anti-TNF therapy is initiated.

Original languageEnglish (US)
Pages (from-to)2233-2240.e2
JournalClinical Gastroenterology and Hepatology
Volume13
Issue number13
DOIs
StatePublished - Dec 1 2015

Fingerprint

Immunologic Factors
Crohn Disease
Meta-Analysis
Tumor Necrosis Factor-alpha
Placebos
Safety
Odds Ratio
Confidence Intervals
Therapeutics
Randomized Controlled Trials
Fistula
Injections
Proxy

Keywords

  • Clinical Trial
  • IBD
  • Immune Suppression
  • Inflammatory Bowel Disease

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-Tumor Necrosis Factor Therapy for Crohn's Disease : A Meta-analysis of Placebo-controlled Trials. / Jones, Jennifer L.; Kaplan, Gilaad G.; Peyrin-Biroulet, Laurent; Baidoo, Leonard; Devlin, Shane; Melmed, Gil Y.; Tanyingoh, Divine; Raffals, Laura E. H.; Irving, Peter; Kozuch, Patricia; Sparrow, Miles; Velayos, Fernando; Bressler, Brian; Cheifetz, Adam; Colombel, Jean Frederic; Siegel, Corey A.

In: Clinical Gastroenterology and Hepatology, Vol. 13, No. 13, 01.12.2015, p. 2233-2240.e2.

Research output: Contribution to journalArticle

Jones, JL, Kaplan, GG, Peyrin-Biroulet, L, Baidoo, L, Devlin, S, Melmed, GY, Tanyingoh, D, Raffals, LEH, Irving, P, Kozuch, P, Sparrow, M, Velayos, F, Bressler, B, Cheifetz, A, Colombel, JF & Siegel, CA 2015, 'Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-Tumor Necrosis Factor Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled Trials', Clinical Gastroenterology and Hepatology, vol. 13, no. 13, pp. 2233-2240.e2. https://doi.org/10.1016/j.cgh.2015.06.034
Jones, Jennifer L. ; Kaplan, Gilaad G. ; Peyrin-Biroulet, Laurent ; Baidoo, Leonard ; Devlin, Shane ; Melmed, Gil Y. ; Tanyingoh, Divine ; Raffals, Laura E. H. ; Irving, Peter ; Kozuch, Patricia ; Sparrow, Miles ; Velayos, Fernando ; Bressler, Brian ; Cheifetz, Adam ; Colombel, Jean Frederic ; Siegel, Corey A. / Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-Tumor Necrosis Factor Therapy for Crohn's Disease : A Meta-analysis of Placebo-controlled Trials. In: Clinical Gastroenterology and Hepatology. 2015 ; Vol. 13, No. 13. pp. 2233-2240.e2.
@article{2b09b35cf7ef444586860877f3f10bed,
title = "Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-Tumor Necrosis Factor Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled Trials",
abstract = "Background & Aims: There is debate over whether patients with Crohn's disease who start anti-tumor necrosis factor (TNF) therapy after failed immunomodulator therapy should continue to receive concomitant immunomodulators. We conducted a meta-analysis of subgroups from randomized controlled trials (RCTs) of anti-TNF agents to compare the efficacy and safety of concomitant immunomodulator therapy vs anti-TNF monotherapy. Methods: We performed a systematic review of literature published from 1980 through 2008 and identified 11 RCTs of anti-TNF agents in patients with luminal or fistulizing Crohn's disease. We excluded RCTs of patients who were naive to anti-TNF and immunomodulator therapy. The primary end points were clinical response at weeks 4-14 and 24-30 and remission at weeks 24-30. Secondary end points included infusion site or injection site reactions and selected adverse events. A priori subgroup analyses were performed to evaluate fistula closure and the efficacy and safety of combination therapy with different anti-TNF agents. Results: Overall, combination therapy was no more effective than monotherapy in inducing 6-month remission (odds ratio [OR], 1.02; 95{\%} confidence interval [CI], 0.80-1.31), inducing a response (OR, 1.08; 95{\%} CI, 0.79-1.48), maintaining a response (OR, 1.53; 95{\%} CI, 0.67-3.49), or inducing partial (OR, 1.25; 95{\%} CI, 0.84-1.88) or complete fistula closure (OR, 1.10; 95{\%} CI, 0.68-1.78). In subgroup analyses of individual anti-TNF agents, combination therapy was not more effective than monotherapy in inducing 6-month remission in those treated with infliximab (OR, 1.73; 95{\%} CI, 0.97-3.07), adalimumab (OR, 0.88; 95{\%} CI, 0.58-1.35), or certolizumab (OR, 0.93; 95{\%} CI, 0.65-1.34). Overall, combination therapy was not associated with an increase in adverse events, but inclusion of infliximab was associated with fewer injection site reactions (OR, 0.46; 95{\%} CI, 0.26-0.79.). Conclusions: On the basis of a meta-analysis, continued use of immunomodulator therapy after starting anti-TNF therapy is no more effective than anti-TNF monotherapy in inducing or maintaining response or remission. RCTs are needed to adequately assess the efficacy of continued immunomodulator therapy after anti-TNF therapy is initiated.",
keywords = "Clinical Trial, IBD, Immune Suppression, Inflammatory Bowel Disease",
author = "Jones, {Jennifer L.} and Kaplan, {Gilaad G.} and Laurent Peyrin-Biroulet and Leonard Baidoo and Shane Devlin and Melmed, {Gil Y.} and Divine Tanyingoh and Raffals, {Laura E. H.} and Peter Irving and Patricia Kozuch and Miles Sparrow and Fernando Velayos and Brian Bressler and Adam Cheifetz and Colombel, {Jean Frederic} and Siegel, {Corey A.}",
year = "2015",
month = "12",
day = "1",
doi = "10.1016/j.cgh.2015.06.034",
language = "English (US)",
volume = "13",
pages = "2233--2240.e2",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",
number = "13",

}

TY - JOUR

T1 - Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-Tumor Necrosis Factor Therapy for Crohn's Disease

T2 - A Meta-analysis of Placebo-controlled Trials

AU - Jones, Jennifer L.

AU - Kaplan, Gilaad G.

AU - Peyrin-Biroulet, Laurent

AU - Baidoo, Leonard

AU - Devlin, Shane

AU - Melmed, Gil Y.

AU - Tanyingoh, Divine

AU - Raffals, Laura E. H.

AU - Irving, Peter

AU - Kozuch, Patricia

AU - Sparrow, Miles

AU - Velayos, Fernando

AU - Bressler, Brian

AU - Cheifetz, Adam

AU - Colombel, Jean Frederic

AU - Siegel, Corey A.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Background & Aims: There is debate over whether patients with Crohn's disease who start anti-tumor necrosis factor (TNF) therapy after failed immunomodulator therapy should continue to receive concomitant immunomodulators. We conducted a meta-analysis of subgroups from randomized controlled trials (RCTs) of anti-TNF agents to compare the efficacy and safety of concomitant immunomodulator therapy vs anti-TNF monotherapy. Methods: We performed a systematic review of literature published from 1980 through 2008 and identified 11 RCTs of anti-TNF agents in patients with luminal or fistulizing Crohn's disease. We excluded RCTs of patients who were naive to anti-TNF and immunomodulator therapy. The primary end points were clinical response at weeks 4-14 and 24-30 and remission at weeks 24-30. Secondary end points included infusion site or injection site reactions and selected adverse events. A priori subgroup analyses were performed to evaluate fistula closure and the efficacy and safety of combination therapy with different anti-TNF agents. Results: Overall, combination therapy was no more effective than monotherapy in inducing 6-month remission (odds ratio [OR], 1.02; 95% confidence interval [CI], 0.80-1.31), inducing a response (OR, 1.08; 95% CI, 0.79-1.48), maintaining a response (OR, 1.53; 95% CI, 0.67-3.49), or inducing partial (OR, 1.25; 95% CI, 0.84-1.88) or complete fistula closure (OR, 1.10; 95% CI, 0.68-1.78). In subgroup analyses of individual anti-TNF agents, combination therapy was not more effective than monotherapy in inducing 6-month remission in those treated with infliximab (OR, 1.73; 95% CI, 0.97-3.07), adalimumab (OR, 0.88; 95% CI, 0.58-1.35), or certolizumab (OR, 0.93; 95% CI, 0.65-1.34). Overall, combination therapy was not associated with an increase in adverse events, but inclusion of infliximab was associated with fewer injection site reactions (OR, 0.46; 95% CI, 0.26-0.79.). Conclusions: On the basis of a meta-analysis, continued use of immunomodulator therapy after starting anti-TNF therapy is no more effective than anti-TNF monotherapy in inducing or maintaining response or remission. RCTs are needed to adequately assess the efficacy of continued immunomodulator therapy after anti-TNF therapy is initiated.

AB - Background & Aims: There is debate over whether patients with Crohn's disease who start anti-tumor necrosis factor (TNF) therapy after failed immunomodulator therapy should continue to receive concomitant immunomodulators. We conducted a meta-analysis of subgroups from randomized controlled trials (RCTs) of anti-TNF agents to compare the efficacy and safety of concomitant immunomodulator therapy vs anti-TNF monotherapy. Methods: We performed a systematic review of literature published from 1980 through 2008 and identified 11 RCTs of anti-TNF agents in patients with luminal or fistulizing Crohn's disease. We excluded RCTs of patients who were naive to anti-TNF and immunomodulator therapy. The primary end points were clinical response at weeks 4-14 and 24-30 and remission at weeks 24-30. Secondary end points included infusion site or injection site reactions and selected adverse events. A priori subgroup analyses were performed to evaluate fistula closure and the efficacy and safety of combination therapy with different anti-TNF agents. Results: Overall, combination therapy was no more effective than monotherapy in inducing 6-month remission (odds ratio [OR], 1.02; 95% confidence interval [CI], 0.80-1.31), inducing a response (OR, 1.08; 95% CI, 0.79-1.48), maintaining a response (OR, 1.53; 95% CI, 0.67-3.49), or inducing partial (OR, 1.25; 95% CI, 0.84-1.88) or complete fistula closure (OR, 1.10; 95% CI, 0.68-1.78). In subgroup analyses of individual anti-TNF agents, combination therapy was not more effective than monotherapy in inducing 6-month remission in those treated with infliximab (OR, 1.73; 95% CI, 0.97-3.07), adalimumab (OR, 0.88; 95% CI, 0.58-1.35), or certolizumab (OR, 0.93; 95% CI, 0.65-1.34). Overall, combination therapy was not associated with an increase in adverse events, but inclusion of infliximab was associated with fewer injection site reactions (OR, 0.46; 95% CI, 0.26-0.79.). Conclusions: On the basis of a meta-analysis, continued use of immunomodulator therapy after starting anti-TNF therapy is no more effective than anti-TNF monotherapy in inducing or maintaining response or remission. RCTs are needed to adequately assess the efficacy of continued immunomodulator therapy after anti-TNF therapy is initiated.

KW - Clinical Trial

KW - IBD

KW - Immune Suppression

KW - Inflammatory Bowel Disease

UR - http://www.scopus.com/inward/record.url?scp=84947422075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947422075&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2015.06.034

DO - 10.1016/j.cgh.2015.06.034

M3 - Article

C2 - 26142167

AN - SCOPUS:84947422075

VL - 13

SP - 2233-2240.e2

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

SN - 1542-3565

IS - 13

ER -